2 型糖尿病市場，依藥物類別、依給藥途徑、依最終用戶、依配銷通路、依地理位置

預計 2024 年 2 型糖尿病市值為 398.7 億美元，預計到 2031 年將達到 671.4 億美元，2024 年至 2031 年年複合成長率(CAGR) 為 7.7%。

圖 1. 2 型糖尿病市場佔有率 (%)（依地區），2024 年

2型糖尿病是一種慢性代謝性疾病，其特徵是由於胰島素抗性或胰島素相對缺乏而導致高血糖。它是最常見的糖尿病形式，佔全球所有糖尿病診斷病例的 90% 以上。該疾病是全球主要的公共衛生問題，因為已開發國家和發展中國家的肥胖水平增加以及人口老化導致其盛行率不斷上升。 2型糖尿病管理和治療的市場規模龐大且穩定成長。目前的治療方案旨在透過增加身體對胰島素的敏感性、減少肝臟中葡萄糖的產生、延遲腸道對葡萄糖的吸收或增加剩餘功能性BETA細胞的胰島素分泌來降低血糖水平。

市場動態：

全球第2型糖尿病市場的主要促進因素是肥胖和體力活動水平低下，尤其是在城市人口中，導致第2型糖尿病發病率上升。根據美國疾病管制與預防中心在 2023 年 4 月發表的一篇文章，美國約有 3,800 萬人患有糖尿病，約佔每 10 人中就有 1 人患有糖尿病。這些病例中約 90-95% 被歸類為第 2 型糖尿病。雖然第 2 型糖尿病傳統上多見於 45 歲及以上的人群，但其在兒童、青少年和年輕人中的發病率呈上升趨勢。加強研究力度開發更有效、副作用更少的藥物也帶來了巨大的成長機會。然而，與糖尿病護理和管理相關的高昂費用阻礙了低收入和中等收入國家更廣泛地獲得治療。嚴格的法規和漫長的藥品核准期限也帶來了課題。

研究的主要特點：

• 該報告對全球第2型糖尿病市場進行了深入分析，並提供了以2023年為基準年的預測期（2024-2031年）的市場規模（十億美元）和年複合成長率（CAGR%）。
• 它闡明了不同區隔市場的潛在收入成長機會，並解釋了該市場有吸引力的投資主張矩陣。
• 這項研究還提供了有關市場促進因素、限制因素、機會、新產品發布或批准、市場趨勢、區域前景以及主要參與者採取的競爭策略的重要見解。
• 它根據以下參數描述了全球 2 型糖尿病市場的主要參與者——公司亮點、產品組合、主要亮點、財務表現和策略。
• 該報告的見解將使行銷人員和公司管理當局能夠就未來的產品發布、類型升級、市場擴張和行銷策略做出明智的決策。
• 全球 2 型糖尿病市場報告迎合了該行業的各個利益相關者，包括投資者、供應商、產品製造商、分銷商、新進業者和財務分析師。
• 利害關係人可以透過用於分析全球 2 型糖尿病市場的各種策略矩陣輕鬆做出決策。

目錄

第1章：研究目標與假設

• 研究目標
• 假設
• 縮寫

第 2 章：市場範圍

• 報告說明
  • 市場定義和範圍
• 執行摘要
• Coherent Opportunity Map (COM)

第 3 章：市場動態、法規與趨勢分析

• 市場動態
  • 促進要素
  • 限制
  • 市場機會
• 影響分析
• 市場走向
• 最近的發展
• 收購和合作場景
• 技術概覽
• 監管場景
• 定價分析
• PEST分析

第 4 章：全球 2 型糖尿病市場 - 冠狀病毒 (COVID-19) 大流行的影響

• 整體影響
• 政府舉措
• COVID-19 對市場的影響

第 5 章：2019 - 2031 年全球 2 型糖尿病市場（依藥物類別）（十億美元）

• 概述
• 二肽基肽酶 4 抑制劑
• 胰高血糖素樣胜肽 1 受體激動劑
• 雙胍類
• 鈉-葡萄糖協同轉運蛋白 2 (SGLT2) 抑制劑
• 其他

第 6 章：2019 年至 2031 年全球 2 型糖尿病市場（依給藥途徑）（十億美元）

• 概述
• 口服
• 注射用

第 7 章：全球 2 型糖尿病市場，依最終用戶分類，2019 - 2031 年（十億美元）

• 概述
• 家庭護理設置
• 醫院和診所
• 學術及研究機構
• 其他

第 8 章：全球 2 型糖尿病市場，依配銷通路，2019 年 - 2031 年，（十億美元）

• 概述
• 醫院藥房
• 零售藥局
• 網路藥局

第 9 章：2019 - 2031 年全球 2 型糖尿病市場（依地區）（十億美元）

• 介紹
• 北美洲
• 美國
• 加拿大
• 拉丁美洲
• 巴西
• 墨西哥
• 阿根廷
• 拉丁美洲其他地區
• 歐洲
• 英國
• 德國
• 義大利
• 法國
• 西班牙
• 俄羅斯
• 歐洲其他地區
• 亞太地區
• 中國
• 印度
• 日本
• 東協
• 澳洲
• 韓國
• 亞太地區其他地區
• 中東
• 海灣合作理事會
• 以色列
• 中東其他地區
• 非洲
• 北非
• 中非
• 南非

第 10 章：競爭格局

• 公司簡介
  • Novo Nordisk
  • Sanofi
  • Eli Lilly and Company
  • Merck & Co., Inc.
  • Boehringer Ingelheim
  • AstraZeneca PLC
  • Takeda Pharmaceutical Company Limited
  • Novartis AG
  • GlaxoSmithKline plc
  • Pfizer Inc.
  • Daiichi Sankyo Company, Limited
  • Roche Holding AG
  • Sun Pharmaceutical Industries Ltd.
  • Lupin Limited
  • Dr. Reddy's Laboratories Ltd.
  • Aurobindo Pharma Limited
  • Torrent Pharmaceuticals Limited

第 11 章：分析師觀點

• 命運之輪
• 分析師觀點
• 連貫的機會圖

第 12 章：參考文獻與研究方法

• 參考
• 研究方法論

The type 2 diabetes market is estimated to be valued at USD 39.87 Bn in 2024 and is expected to reach USD 67.14 Bn by 2031, growing at a compound annual growth rate (CAGR) of 7.7% from 2024 to 2031.

Figure 1.Type 2 Diabetes Market Share (%), By Region, 2024

Type 2 diabetes is a chronic metabolic disease characterized by high blood sugar levels due to insulin resistance or relative lack of insulin. It is the most common form of diabetes accounting for over 90% of all diagnosed cases of diabetes worldwide. The disease is a major global public health concern due to its rising prevalence driven by increasing obesity levels as well as aging populations across both developed and developing countries. The market size for type 2 diabetes management and treatment is vast and growing steadily. Current therapeutic options aim to lower blood sugar levels by increasing the body's sensitivity to insulin, reducing glucose production in the liver, delaying glucose absorption from the intestine, or increasing insulin secretion from the remaining functioning beta cells.

Market Dynamics:

The global type 2 diabetes market is primarily driven by the increasing prevalence of obesity and low physical activity levels especially among urban populations leading to the rising incidence of type 2 diabetes. According to an article published by the Centers for Disease Control and Prevention in April 2023, about 38 million individuals in the U.S. are affected by diabetes, representing roughly one out of every 10 people. Approximately 90-95% of these cases are classified as type 2 diabetes. While type 2 diabetes traditionally manifests in individuals aged 45 and older, there is a growing trend of its occurrence among children, teenagers, and young adults. Increased research efforts to develop more effective medications with fewer side effects also present significant growth opportunities. However, high costs associated with diabetes care and management inhibits broader access to treatment in low and middle-income countries. Stringent regulations and long drug approval timelines also pose challenges.

Key Features of the Study:

• This report provides an in-depth analysis of the global type 2 diabetes market, and provides market size (USD BN) and compound annual growth rate (CAGR %) for the forecast period (2024-2031), considering 2023 as the base year
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global type 2 diabetes market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Novo Nordisk, Sanofi, Eli Lilly and Company, Merck & Co., Inc., Boehringer Ingelheim, AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Novartis AG, GlaxoSmithKline plc, Pfizer Inc., Daiichi Sankyo Company, Limited, Abbott Laboratories, Roche Holding AG, Sun Pharmaceutical Industries Ltd., Lupin Limited, Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Limited, and Torrent Pharmaceuticals Limited
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global type 2 diabetes market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global type 2 diabetes market

Market Segmentation

• By Drug Class:
  • Dipeptidyl Peptidase-4 Inhibitors
  • Glucagon-like peptide 1 receptor agonists
  • Biguanides
  • Sodium-glucose cotransporter 2 (SGLT2) inhibitors
  • Others
• By Route of Administration:
  • Oral
  • Parenteral
• By End User:
  • Homecare Settings
  • Hospitals & Clinics
  • Academic & Research Institutes
  • Others
• By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • Novo Nordisk
  • Sanofi
  • Eli Lilly and Company
  • Merck & Co., Inc.
  • Boehringer Ingelheim
  • AstraZeneca PLC
  • Takeda Pharmaceutical Company Limited
  • Novartis AG
  • GlaxoSmithKline plc
  • Pfizer Inc.
  • Daiichi Sankyo Company, Limited
  • Abbott Laboratories
  • Roche Holding AG
  • Sun Pharmaceutical Industries Ltd.
  • Lupin Limited
  • Reddy's Laboratories Ltd.
  • Aurobindo Pharma Limited
  • Torrent Pharmaceuticals Limited

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Drug Class
  • Market Snapshot, By Route of Administration
  • Market Snapshot, By End User
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• Market Trends
• Recent Developments
• Acquisitions and Partnerships Scenario
• Technology Overview
• Regulatory Scenario
• Pricing Analysis
• PEST Analysis

4. Global Type 2 Diabetes Market - Impact of Coronavirus (COVID-19) Pandemic

• Overall Impact
• Government Initiatives
• COVID-19 impact on the market

5. Global Type 2 Diabetes Market, By Drug Class, 2019 - 2031, (USD BN)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Dipeptidyl Peptidase-4 Inhibitors
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
• Glucagon-like peptide 1 receptor agonists
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
• Biguanides
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
• Sodium-glucose cotransporter 2 (SGLT2) inhibitors
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)

6. Global Type 2 Diabetes Market, By Route of Administration, 2019 - 2031, (USD BN)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Oral
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
• Parenteral
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)

7. Global Type 2 Diabetes Market, By End User, 2019 - 2031, (USD BN)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Homecare Settings
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
• Hospitals & Clinics
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
• Academic & Research Institutes
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)

8. Global Type 2 Diabetes Market, By Distribution Channel, 2019 - 2031, (USD BN)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Hospital Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
• Retail Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
• Online Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)

9. Global Type 2 Diabetes Market, By Region, 2019 - 2031, (USD BN)

• Introduction
  • Market Share Analysis, By Region, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, For Region, 2020-2031
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
• U.S.
• Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
• U.K.
• Germany
• Italy
• France
• Spain
• Russia
• Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
• China
• India
• Japan
• ASEAN
• Australia
• South Korea
• Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
• GCC
• Israel
• Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (USD BN)
• North Africa
• Central Africa
• South Africa

10. Competitive Landscape

• Company Profiles
  • Novo Nordisk*
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Market Strategies
  • Sanofi
  • Eli Lilly and Company
  • Merck & Co., Inc.
  • Boehringer Ingelheim
  • AstraZeneca PLC
  • Takeda Pharmaceutical Company Limited
  • Novartis AG
  • GlaxoSmithKline plc
  • Pfizer Inc.
  • Daiichi Sankyo Company, Limited
  • Roche Holding AG
  • Sun Pharmaceutical Industries Ltd.
  • Lupin Limited
  • Dr. Reddy's Laboratories Ltd.
  • Aurobindo Pharma Limited
  • Torrent Pharmaceuticals Limited

11. Analyst View

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

12. References and Research Methodology

• References
• Research Methodology
• About us and Sales Contact